Making a Drop Down List in a DBGrid

Making a Drop Down List in a DBGrid Want to make the best data editing grid ever? Below are instructions for building a user interface for editing lookup fields Inside a DBGrid. Specifically, well be looking at how to place a DBLookupComboBox into a cell of a DBGrid. What this will do is call upon information from a data source that will be used to populate a drop-down box. To show a DBLookupComboBox inside a cell of a DBGrid, you first need to make one available at run time... Create a Lookup With a DBLookupComboBox Select the Data controls page on the Component Palette and pick a DBLookupComboBox. Drop one anywhere on the form and leave the default name of DBLookupComboBox1. It doesnt matter where you put it since most of the time, it will be invisible or floating over the grid. Add one more DataSource and DataSet component to fill the combo box with values. Drop a TDataSource (with the name DataSource2) and TAdoQuery (name it AdoQuery1) anywhere on the form. For a DBLookupComboBox to work properly, several more properties must be set; theyre the key to the lookup connection: DataSource and DataField determine the main connection. The DataField is a field into which we insert the looked-up values.ListSource is the source of the lookup dataset.KeyField identifies the field in the ListSource that must match the value of the DataField field.ListFields is the field(s) of the lookup dataset that are actually displayed in the combo. ListField can show more than one field but multiples should be separated by semicolons.You have to set large enough value for the DropDownWidth (of a ComboBox) to really see multiple columns of data.Heres how to set all the important properties from code (in the forms OnCreate event handler): procedure TForm1.FormCreate(Sender: TObject);beginwith DBLookupComboBox1 dobegin DataSource : DataSource1; // - AdoTable1 - DBGrid1 ListSource : DataSource2; DataField : AuthorEmail; // from AdoTable1 - displayed in the DBGrid KeyField : Email; ListFields : Name; Email; Visible : False; end; DataSource2.DataSet : AdoQuery1; AdoQuery1.Connection : AdoConnection1; AdoQuery1.SQL.Text : SELECT Name, Email FROM Authors; AdoQuery1.Open;end; Note: When you want to display more than one field in a DBLookupComboBox, like in the above example, you have to make sure that all columns are visible. This is done by setting the DropDownWidth property. However, youll see that initially, you have to set this to a very large value which results in dropped list being too wide (in most cases). One workaround is to set the DisplayWidth of a particular Field shown in a drop-down list. This code, placed inside the OnCreate event for the form, ensures that both the author name and its email are displayed inside the drop-down list: AdoQuery1.FieldByName(Email).DisplayWidth:10;AdoQuery1.FieldByName(Name).DisplayWidth:10;AdoQuery1.DropDownWidth:150; Whats left for us to do, is to actually make a combo box hover over a cell (when in edit mode), displaying the AuthorEmail field. First, we need to make sure the DBLookupComboBox1 is moved and sized over the cell in which the AuthorEmail field is displayed. procedure TForm1.DBGrid1DrawColumnCell (Sender: TObject; const Rect: TRect; DataCol: Integer; Column: TColumn; State: TGridDrawState);beginif (gdFocused in State) thenbeginif (Column.Field.FieldName DBLookupComboBox1.DataField) thenwith DBLookupComboBox1 do begin Left : Rect.Left DBGrid1.Left 2; Top : Rect.Top DBGrid1.Top 2; Width : Rect.Right - Rect.Left; Width : Rect.Right - Rect.Left; Height : Rect.Bottom - Rect.Top; Visible : True; end; endend; Next, when we leave the cell, we have to hide the combo box: procedure TForm1.DBGrid1ColExit(Sender: TObject);beginif DBGrid1.SelectedField.FieldName DBLookupComboBox1.DataField then DBLookupComboBox1.Visible : Falseend; Note that when in editing mode, all keystrokes are going to the DBGrids cell but we have to make sure they are sent to the DBLookupComboBox. In the case of a DBLookupComboBox, we are primarily interested in the [Tab] key; it should move the input focus to the next cell. procedure TForm1.DBGrid1KeyPress(Sender: TObject; var Key: Char);beginif (key Chr(9)) then Exit; if (DBGrid1.SelectedField.FieldName DBLookupComboBox1.DataField) thenbegin DBLookupComboBox1.SetFocus; SendMessage(DBLookupComboBox1.Handle, WM_Char, word(Key), 0); endend; When you pick an item (row) from a DBLookupComboBox, the value or the corresponding KeyField field is stored as the value of the DataField field.

The Awakening and Into The Wild Essay Example | Topics and Well Written Essays - 1000 words

The Awakening and Into The Wild - Essay Example Into the Wild, on the other hand, is a 1996 factual book written by Jon Krakauer. It is an extension of the author’s 9,000-word piece on Christopher McCandless known as the Death of an Innocent, which was published in the January issue of Outside, in 1993. This novel tackles the issues of how to be accepted and recognized in society, and how finding yourself, at times, clashes with being an active member of the society. In this reading, a reader could see that Chris McCandless was behind left to find some kind of enlightenment. He endeavors to find his path in the wild with little material assets since "it made the journey more fun" (Krakauer 32). His intense risk-taking habit was the hubris that finally led to his downfall. These two writings focus on theme them of how to be accepted into society with The Awakening incorporating a female character as the protagonist and Into the Wild incorporating a male character as the protagonist. This paper will discuss how the two writin g bring out these themes (the effects of self-expression) through analysis of character roles, conflict resolution and literary devices. Edna is the central character in The Awakening, which also refers to her title. The 28 years old woman, who is wifed to a New Orleans businessman, instantly finds herself dissatisfied with her husband, as well as the limited conservative way of living that it dictates (Chopin 30). She appears from her semi-conscious situation of a devoted companion and a mother to a situation of complete awareness, through which she finds her own identity and acts on her own desires for sexual and emotional satisfaction. Through a series of "awakenings", Edna turns into a shockingly independent girl and is accountable only to her personal passions and urges (Chopin 189). Sadly, Edna’s experience (awakening) isolates her form other members of society, which led to her state of complete solitude. Christopher McCandless was a smart, optimistic young man who dee med that life is best lived in isolation, otherwise in nature. He spent two full years putting his theory into practice in the "wild-wests" of the U.S before moving into Alaska. However, he was unprepared of this journey and eventually starved to death (Krakauer 40). What these two accounts show us is that these two character where on endeavors to find themselves in opposition to the accepted societal ways, but eventually ended up harming themselves. Edna, in the awakening, ended up in utter solitude the made her to commit suicide and McCandless, in Into the Wild, ended up starving to death. Edna’s breakthrough of ways to express herself brings about the disclosure of her long-repressed emotions. Through her experience, she learns at least three fresh "languages" (Chopin 78). First and foremost, she learns the style of expression of Creole women in Grand Isle. In spite of their chastity, Creole women converse freely and share their thoughts openly. Their openness initially st unned Edna, but she soon was free about it. Edna discovered that she can face her sexuality and feelings directly, devoid of any fear. Once some of her Creole friends reveal to her that it is fine to dwell on one’

Strategic Management Essay Example | Topics and Well Written Essays - 2500 words - 20

Strategic Management - Essay Example The company believes in developing exceptional flow experience for its people. In this study different strategic frameworks have been included to determine strategic position of the firm in market place. These models are PESTLE analysis, Porter’s five forces model, competitor array, strategic group mapping, GE-McKinsey 9 box matrix, Bowman’s strategy clock, Ansoff’s matrix and TOWS matrix. The digital marketing strategy of the company has been outlined which shall support KONE in terms of offering new products to new geographical markets. There is intense competition in the industry and it can be addressed only through implementing innovating business strategies. KONE needs to explore new market opportunities through offering new products to target segment. Digital marketing strategies shall help the firm to easily access target market and acquire desirable profit margins. The mission or value statement of the company is to create best flow experience for people. KONE is regarded as the global leader in context of elevator industry. From past many years the company is actively indulged in offering superior quality escalators or elevators to its client base. KONE aims at achieving cost competitiveness and operational excellence through innovative processes and people leadership. KONE’s strategic objectives can be divided into four dimensions such as expanding base of loyal customers, initiating employee empowerment, enabling best experience for users and seeking profitable growth. Financial objective is to grow at a rapid rate in comparison to market growth rate. KONE aims at enhancing working capital rotation and reaching 16% EBIT. External environmental analysis indicates all possible external influences which have significant impact on business operations. KONE Great Britain has been operating in elevator and escalator industry from past many years. The entire business operations of KONE can be categorized into two distinct

Legal Limits to Press Freedom Essay Example | Topics and Well Written Essays - 3250 words

Legal Limits to Press Freedom - Essay Example The paper chose this topic on the belief that the right to privacy and right to fair trial are inter-related in a particular way: the right to privacy of a defendant in a court case is violated twice over if news reporters run commentaries that tend to prejudge the case. In fact, these citizen's rights are lumped together as primary concerns of the European Convention on Human Rights, which exhorts member states to adopt measures that would balance the right of the public to be informed and the right to privacy and to fair and unimpeded administration of justice (5). Trial by publicity and media intrusion into the private affairs of citizens are common practices in UK, where tabloid journalism had become so licentious that the Press Complaints Commission (PCC) was reorganized and strengthened in 1991 to deal with media abuses on a self-regulatory basis. On invasion of privacy, hardly a week passes by without a movie celebrity, politician or royalty suing a media organization in London for such intrusion. Violation of the 1981 Contempt of Court Act is also rampant. This paper focuses its attention on the perceived problem regarding UK media's frequent attempt to cross the line between press freedom and the right of individuals to privacy and to fair trial. ... with media abuses on a self-regulatory basis. On invasion of privacy, hardly a week passes by without a movie celebrity, politician or royalty suing a media organization in London for such intrusion. Violation of the 1981 Contempt of Court Act is also rampant. This paper focuses its attention on the perceived problem regarding UK media's frequent attempt to cross the line between press freedom and the right of individuals to privacy and to fair trial. Consequently, the essay looks into the recorded cases of specific media violations of these two citizens' rights, as well as of laws that address those abuses. A significant portion of the paper will illumine the outcomes of the relevant cases after they were brought to court as a tort or criminal complaint. Some of the questions the rest of the essay will seek answers to: Have there been any UK media men penalized for such offenses What was the line of defense used by those favored by the courts What damage does violation of these media laws do on the lives of private citizens Does faithful observance of media laws affect and limit the performance of media men in unearthing the truth and safeguarding public interest 2. Media Practice In UK, government control of media exists only in matters relating to the Official Secrets Act and violation of the existing libel laws. Outside of these two areas, media practice is practically free of any kind of restraints, guided only by a Code of Practice set by the PCC under a climate of self-regulation. There are 16 provisos in the Code, at least half of which concern people's right to privacy while the other half relate to media coverage of court cases. The clauses involving privacy intrusion include harassment,

Effectiveness of Second Generation Tyrosine Kinase Inhibitor

Effectiveness of Second Generation Tyrosine Kinase Inhibitor Susmi Suresh Effectiveness of Second Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Phase Chronic Myeloid Leukaemia: a systematic review Abstract Background: Chronic Myelogenous Leukemia (CML), a cancer of the myeloid lineage, affects around 15 per 100,000 people per year in the UK. Tyrosine Kinase Inhibitor (TKI) oral therapy is used to target the causative BCR-Abl protein. Second-generation TKIs namely dasatinib and nilotinib are understood to be more potent than the first-generation prototype imatinib. However, cost-effectiveness is hindering the widespread use of second-generation TKIs. The patency of these drugs will expire in the immediate future and so, the prices of these are expected to fall. A clear understanding of the efficacy of the potent second-generation TKIs will aid decision-making bodies such as NICE UK to form guidelines on front-line drugs. This review aims to collect and examine evidence from current literature on the effectiveness of second-generation TKIs in the treatment of chronic phase CML. Method: A systematic search of major databases was carried out and the results were screened using specific inclusion and exclusion criteria. Five major randomised controlled trials were identified. Data extraction and risk of bias assessment were carried out using standardised forms developed specifically for RCTs by the Cochrane Collaboration. Quality assessment of the trials was performed using the CASP tool. Results: The five chosen RCTs were the DASISION trial, the S0325 trial and the SPIRIT 2 which compared dasatinib with imatinib, and the ENESTnd trial and the ENESTchina trial which compared nilotinib with imatinib. A participant pool of 2692 patients had a mean age of 61 years and similar features. A total of n=789 and n=697 patients were randomly assigned to dasatinib and nilotinib arms. Second-generation TKIs were associated with greater response rates in patients than imatinib; for example, dasatinib was associated with an odds ratio (OR) of 0.0803 (95%CI 0.0434 to 0.1489 Pin the S0325 trial, and nilotinib OR= 0.1772 (95%CI 0.1217 to 0.2581 Pin the ENESTnd trial. Conclusion: Current evidence points to a greater efficacy of second-generation TKIs, namely dasatinib and nilotinib, than imatinib. Adverse events (AEs) were reported for all three drugs. Due to the lack of a direct comparison between second-generation TKIs, the effectiveness of dasatinib over nilotinib could not be inferred. In order to aid bodies such as NICE to choose the most apt and safe TKI for use as a first-line treatment choice, it is suggested that future studies aim for a direct comparison. Toxicity data should also be generated to supplement this process. Introduction       Chronic Myelogenous Leukaemia (CML), a cancer of the myeloid lineage, accounts for 8% of adult leukaemias in the UK (1). This acquired genetic disorder causes the pluripotent myeloid stem cells in the bone marrow to undergo unregulated growth (2). A proliferative advantage thus results in patients having abnormally increased levels of serum leukocytes. The WHO ICD-10 classifies this disease as a malignant neoplasm with Philadelphia positive, t(9:22) (q34:q11) translocation and crisis of blast cells. With an annual incidence of 14.8 per 100,000 per year (3), leukaemia, along with its subtypes, is the twelfth most common cancer in the UK. The disease has a male predominance and its incidence increases with age (4). Although no causative environmental leukomogens have been identified, several studies have observed higher incidence in patients exposed to very high doses of ionising radiation (5). CML is often triphasic, with an initial chronic phase (CML-CP) followed by the advanced phases of accelerated (intermediate) phase and a final blast crisis- all with deteriorating laboratory profiles and clinical signs. Tyrosine kinase inhibitor (TKI) oral therapy has been used to extend the clinical course (particularly that of CML-CP). CML today is one of the fewest cancers which can be treated to attain 79% survival rates (6). Since the introduction of TKIs, there has been a significant reduction in mortality rates in the UK- from 1.5 per 100,000 in 2000, to 0.6 in 2010 (7); TKI-attributed mortality reduction is however debatable (8). Currently, imatinib is used as first-line treatment and is available to patients in the UK. Approved by the FDA in 2001, imatinib has been shown to be very effective in the treatment of CML. Prognosis is excellent with an increase in 5-year survival rates by 32% since its introduction (9). Hailed as the magic bullet against cancer (10), there have been several setbacks since introduction. Firstly, patients soon developed resistance. This was counteracted with the development of second-generation TKIs: nilotinib and dasatinib for imatinib-resistant (or intolerant) patients (2). Secondly, TKIs are deemed as one of the most expensive cancer drugs. For instance, in countries such as India where the generic forms are used, the cost difference for a month course, when compared to that in the UK, is an astonishing  £4200 and  £620 for imatinib and dasatinib, respectively (11). As a result, the availability of TKIs is strictly regulated by NICE. Whereas NICE recommends nilotinib as a first line drug if the manufacturer makes Nilotinib available with the discount agreed as part of the patient access scheme (PAS), dasatinib is neither a part of PAS nor is it recommended in CML-treatment (12). NICE explicitly comments on the low cost-effectiveness as the major reason for this despite it acknowledging these drugs to be more effective (13). It is to be reminded that NICE uses clinical as well as economic data to form its guidelines. Prices are expected to fall when the patency of TKIs expires in the future. For example, the patency for imatinib will expire in December 2016 in the UK. This may lead to possible alterations in the NICE recommendations and the use of second-generation drugs for first-line treatments may be favoured. Knowledge on the effectiveness of second-generation TKIs will help us shape the choice of appropriate TKIs in the future, when the pharmaceutical industry will be flooded with their generic versions. As such, this review aims to examine current evidence on the effectiveness of second-generation TKIs in the treatment of CML-CP patients. The molecular basics of CML CML is an acquired neoplasm resulting from the formation of an aberrant gene. In the myeloid stem cells of patients, the breakpoint cluster region (BCR) on chromosome 22 and the Abelson murine leukaemia (c-Abl) on chromosome 9 undergo a (9;22) translocation (Figure 1) . This results in the formation of the aberrant BCR-Abl fusion gene which is seen in 95% of patients (who are so referred to as Ph+ve). The BCR-Abl gene is translated into the leukemogenic protein p210BCR-Abl, an aberrant tyrosine kinase (TK) enzyme that is capable of constitutive activity. TKIs inhibit these aberrant TKs. c-Abl, the non-aberrant version of the gene, has a kinase domain which houses the ATP-binding pocket, an SH2 upregulating domain and an SH3 inhibitory domain. The kinase is strictly auto-inhibited and shuttles between the nucleus and the cytoplasm. However, the BCR-Abl TK is localised in the cytoplasm and this is implicated in its constitutive TK activity (Figure 2). In the cytoplasm, it undergoes auto-dimerisation which activates the enzyme by triggering structural alteration. c-Abl works by phosphorylating the Grb2 substrate protein. This activates the SoS effector molecule which facilitates the conversion of Ras-GDP to Ras-GTP. This further activates Raf due to which MEK1/2 is phosphorylated. As a result, ERK, a critical regulator of Cyclin D is also activated. ERK induces the synthesis of Cyclin D, which along with cdk4, determines whether the cell cycle is allowed past the G1 Restriction point. Once past this checkpoint, cell cycle cannot be reversed and so, the resultant daughter cells are produced. Cyclin D phosphorylates retinoblastoma (Rb), which in its inactive state is unphosphorylated and attached to E2F (a transcription factor), and releases E2F. This allows the cell to enter into the S phase (14) to begin DNA replication. Expression of the BCR-Abl gene upregulates proliferation by constitutively activating the Ras signalling pathway (Figure 3); cyclin D is continuously produced. BCR-Abl expression also facilitates anti-apoptosis and disrupts adhesion (Figure 4). A disrupted adhesion to stromal cells and the extracellular matrix reduces the regulatory effect transmitted via focal adhesions (15). Also, clonal expansion is aided by the evasion of apoptosis. Thus, uncontrolled Ras signalling, upregulated anti-apoptosis and disrupted adhesion are understood to lead to the ultimate manifestation of CML   (16). TKIs inhibit these aberrant tyrosine kinases. Imatinib is a competitive antagonist of the tyrosine kinase domain of BCR-Abl (16). Tyrosine kinases exist in active or inactive states, depending on whether the activation loop located on the C-terminal domain is open or closed (Figure 5).In the inactive state, the activation loop is closed and folds towards the ATP-binding pocket (17). Imatinib and nilotinib bind to the inactive conformation (Figure 6) whereas dasatinib binds to both conformations. Several studies have shown second-generation TKIs to be more effective in treating chronic phase CML (18-20). One such study showed that dasatinib was 325-fold more effective than imatinib at inhibiting BCR-Abl in vitro; this is attributed to its ability to bind to multiple conformations (21). Methods (Appendix A) Results Five randomised controlled trials were identified (Table 9). These included three trials- DASISION, Second Phase S0325 and SPIRIT 2- that compared dasatinib with imatinib and two trials- ENESTnd and ENESTchina- that compared nilotinib with imatinib. All of these together show better outcomes for CML-CP patients treated with second-generation TKIs. The primary end point of all these trials, except DASISION and SPIRIT 2, was MMR rates at 12 months. The DASISION trial looked at CCyR at 12 months. The primary endpoint of SPIRIT 2, the largest dasatinib trial, is event-free survival at 5 years. This will only be measured in March 2018 but nevertheless, secondary outcomes such as CCyR rates at 12 months have been published. All other studies also measured CCyR at 12 months as the secondary outcome. The Dasatinib versus Imatinib Study in Treatment-Naive CML Patients (DASISION) (22) The study aimed to find whether patients given dasatinib had a higher CCyR by 12 months of treatment. CCyR and MMR at 12 months were compared for both drugs and it was concluded that dasatinib may improve long-term outcomes in CML-CP patients due to its shorter response time than imatinib (Table 9; Appendix B: CCyR and MMR measurement methods and scale). Considered as a landmark study, these results proved to be pivotal in accepting dasatinib as a standard second-generation TKI. A 5-year follow-up was conducted to understand whether dasatinib can be continued to be considered as a standard therapy for CML-CP patients. The results (Table 10) supported the original finding (23). The Second Phase S0325 Intergroup (South Western Oncology Group, East Cooperative Oncology Group, Cancer and Leukemia Group B and NCI Canada Clinical Trial Group) Trial (24) The study aimed to compare the response rates for dasatinib- and imatinib-treated patients. Following standard clinical measurement of CCyR rates (Appendix B), dasatinib was found to produce more early short-term cytogenetic and molecular response rates (Table 9). However, the study also noted Grade3-4 toxicities in 58% patients in the dasatinib arm, compared to only 35% in the imatinib arm. Toxicity data were not reported in DASISION or SPIRIT2. ST1571 Prospective International Randomised Trial (SPIRIT 2) (25) CCyR response rates for dasatinib- and imatinib-treated patients were compared. The study observed an increased response rate for dasatinib compared to imatinib (Table 9). With these results, the study concluded that dasatinib was favoured in CML-CP treatment. Evaluating Nilotinib Efficacy and Safety in Clinical Trials- Newly Diagnosed Patients (ENESTnd) (26) A multicentre three-arm trial, this aimed to assess the efficacy and safety of nilotinib compared with imatinib. Two groups of patients given different doses of nilotinib were compared to those treated with the standard imatinib dose. CCyR was found to be higher in both nilotinib arms, compared to the imatinib arm (Table 9). The study thus concluded that nilotinib at either doses produced a clinical response better than imatinib. A 5-year follow up (Table 11) aimed to evaluate the long-term outcomes in patients taking nilotinib; MMR and 5-year overall survival (OS) rates of these patients were examined (27). Patients treated with the higher dose of nilotinib were found to have more AEs. Despite this, due to the short-time with which MMR and CCyR were achieved, the study concluded to recommend nilotinib at 300mg twice daily over imatinib. Current evidence provided by DASISION trial and the works of Quintas-Cardama A et al., 2009 and Hochhaus et al., 2009 were referred by the researchers. These directly link shorter response time with increased long-term benefits and reduced risk of progression (28, 29). Evaluating Nilotinib Efficacy and Safety in Clinical Trials- China (ENESTchina) (30) The trial, conducted in Chinese patients, aimed to observe MMR rates at 12 months in nilotinib and imatinib treated patients. Also, conclusions on whether genetic and ethnic factors affect response to treatment were drawn using the results. Whilst MMR showed a similar pattern as seen in the original ENESTnd trial, CCyR at 12 months for the nilotinib arm was lower than the imatinib arm by 3.6%. Since CCyR at 6 months showed an increased rate for nilotinib (66.4% vs 57.1% for imatinib), the study noted this inconsistency to be favouring nilotinib. Previous studies were cited to have observed early CCyR indicative of better response (31, 32). Thus, it was concluded that nilotinib was more effective.   Study Intervention Dosage n Males (%) Median age Lost to follow up (%) CCyR at 12 months MMR at 12 months DASISION Dasatinib 100mg daily 259 56 46 15 83% (95%CI 78-88; P-value 0.01) MMR3x 46% (95%CI 40-52 P-value Imatinib 400mg daily 260 63 49 19 72% (95%CI 66-77; P-value 0.01) 28% (95%CI 23-34; P-value S0325 Dasatinib 100mg daily 123 60 47 na* 84% (95%CI 74-92; P-value 0.040) MMR3 59% (95%CI 48-68; P-value 0.059) Imatinib 400mg daily 123 63 50 na 59 % (95%CI 56-80; P-value 0.040) 44% (95%CI 34-55; P-value) SPIRIT 2 Dasatinib 100mg daily 407 61.4 53 0 53.4% (P-value MMR3 58.4% Imatinib 400mg daily 407 59.2 53 0 41.6% (P-value 43.1% ENESTnd Nilotinib 300mg twice daily 282 56 47 16 80% (P-value MMR3 44% (P-value Nilotinib 400mg twice daily 281 62 47 18 78% (P-value 43% (P-value Imatinib 400mg daily 283 56 46 21 41.6% (P-value 22% (P-value ENESTchina Nilotinib 300mg twice daily 134 67.9 41 na 77.6 (66.4 at 6 months) 52.2% (95%CI 43.4-60.9; P-value Imatinib 400mg daily 133 60.9 39 na 80.5 (57.1 at 6 months) 27.8% (95%CI 20.4-36.3; P-value Table 9 Study Characteristics; (*na= not available; x See Appendix B: Parameters for measuring effectiveness of TKI) Study Intervention Dosage MMR MMR4.5x 5-year OS (HR 1.01; 95%CI 0.58-1.73) Adverse Events* : Drug-related Pleural Effusion DASISION 5-year Follow-up Dasatinib 100mg daily 76 (P-value= 0.0022) 42(P-value= 0.0022) 91% 28% Imatinib 400mg daily 64 (P-value= 0.0251) 33(P-value= 0.0251) 90% 0.8% Table 10 DASISION 5-year Follow-up Study (*No new adverse events were reported; x See Appendix B: Parameters for measuring TKI effectiveness) Study Intervention Dosage MMR4.5 OS Overall Adverse Events ENESTnd 5-year Follow-up Nilotinib 300mg twice daily 54% 93.7% (95%CI 90.8-90.6) 32.9% Pleural Effusion: 1.8% Nilotinib 400mg twice daily 52% 96.2% (95%CI 93.9-98.5) 41.4% Pleural Effusion: 0.7% Imatinib 400mg daily 31% 91.7% (95%CI 88.3-95.0) 32.7% Pleural Effusion: 1.1% Table 11 ENESTnd 5-year Follow-up Study Discussion The pooled data from 2692 patients show that the second-generation TKIs were more effective than the first-generation TKI imatinib. The results from the three RCTs which compare dasatinib with imatinib give an average absolute risk reduction (ARR) of 26.0%; for nilotinib, average ARR is 24.6% (Table 12). Together, second-generation TKIs produce a very promising complete cytogenic response in 253 per 1000 patients per year. As a comparison, a Cochrane systematic review conducted by Aguilar MI et al., 2005 to understand the efficacy of oral anticoagulants in preventing ischemic heart attacks, collected data from five RCTs with a pool of 2313 patients. This showed that warfarin gives an ARR of 4.05% and so the use of warfarin as a common anticoagulant was continued to be supported (33). Hence, a very high combined ARR of 25.3% shown in this review emphasises the potency of second-generation TKIs in treating CML-CP. With continuous treatment using these TKIs, remission can be attained. à ‚      RCT Intervention Odds Ratio Absolute Risk Reduction (ARR %) ARR per 1000 population (per year) DASISION Dasatinib 0.5242 (95%CI 0.3437 to 0.7997 P=0.0027) 0.11089 (11.1%) 110.9 S0325 Dasatinib 0.0803 (95%CI 0.0434 to 0.1489 P 0.55409 (55.45%) 554.1 SPIRIT 2 Dasatinib 0.6217 (95%CI 0.4713 to 0.8203 P= 0.0008) 0.11825 (11.8%) 118.3 ENESTchina Nilotinib 1.1871 (95%CI 0.6578 to 2.1426 P=0.5691) -0.04282 (-4.28%) -42.82 ENESTnd Nilotinib (300mg) 0.1772 (95%CI 0.1217 to 0.2581 P 0.40358 (40.4%) 403.6 Nilotinib (400mg) 0.2025 (95%CI 0.141 to 0.2925 P 0.37672 (37.7%) 376.7 Table 12 Data processed by the review author Dasatinib Trials The DASISION trial was industry-sponsored and as such, the results are to be approached with caution due to a possible risk of bias. However, the largest dasatinib trial, SPIRIT 2 also shows a very similar ARR of 11.8%. Moreover, the European LeukemiaNet Panel used the results from the DASISION and other similar studies to set the 2013 guidelines in the management of CML-CP (34). Hence, the results are widely acknowledged by the scientific community. However, due importance must be given to toxicity data generated from these studies whilst interpreting the results. Whilst DASISION stated that adverse events (AEs) for both arms were similar, toxicity data were not explicitly reported in DASISION and SPIRIT 2 studies. The S0325 trial addressed this issue (See Results). The team suggested that the choice of TKI should only be made based on a patients individualised risk of progression, pre-existing comorbidity and compliance (24). With reference to this, the 5-year follow-up of DASISION emphasised that there were no new events reported outside of the initial 12 month period (23). Nonetheless, both teams reiterated the quick response of dasatinib in treating CML-CP as an indication of its greater efficacy. However, this increased effectiveness becomes equalised in the long-term, with both dasatinib and imatinib producing similar overall survival rates five years post-treatment (23). Nilotinib Trials Compared to dasatinib, the risk of AEs was only slightly increased in nilotinib patients. Unlike the other RCTs, ENESTnd trial observed imatinib-treated patients to have a high risk of AEs. Nausea and diarrhoea were reported in a very high percentage of patients- 41.1% and 46.1% respectively. The molecular mechanisms of AEs are not currently understood and no studies have been trialled in patients to quantify and assess TKI-related AEs. Hence, a clinically-relevant conclusion was not drawn from these results. Limitations One main factor limiting this review is the absence of direct comparative studies between dasatinib and nilotinib. The S0325 trials observed that the standard dose of dasatinib produced more AEs than imatinib and the ENESTnd trial showed that the higher dose of nilotinib produced more AEs than imatinib. However, these observations alone cannot be used to highlight nilotinib over dasatinib. Another limitation is the possibility of selection bias. Currently, numerous on-going clinical trials worldwide aim to compare the various TKIs. However, much data is yet unpublished. These could not be included in this review due to the lack of an appropriate critical appraisal tool, other than the CASP tool used in this review, with more rigorous criteria. Despite these, conclusions drawn from a large pooled study population of 2692 patients remain reliable. Nonetheless, inconsistencies on both efficacy and AEs data were present when comparing the five trials. The ENESTchina trial observed a better result with imatinib at twelve months than nilotinib (OR= 1.1871; 95%CI 0.6578 to 2.1426 P=0.5691). Additionally, the ENESTnd trial reported imatinib to be associated with higher AEs than dasatinib. However, the pooled data show a greater efficacy of dasatinib and nilotinib than imatinib. Dasatinib is also associated with more AEs than standard dose nilotinib and imatinib. The comparability of ENESTchina to other trials could be questioned. Patients from all ethnicities was a definite inclusion criterion and hence this study could not be excluded. The primary aim was to evaluate the efficacy and safety of nilotinibà ¢Ã¢â€š ¬Ã‚ ¦vs imatinibà ¢Ã¢â€š ¬Ã‚ ¦ (in) patients with newly diagnosed P

Tecumseh Essays -- essays research papers

Tecumseh ,Shawnee war chief, was born at Old Piqua, on the Mad River in western Ohio. In 1774, his father, Puckeshinwa, was killed at the Battle of Point Pleasant, and in 1779 his mother, Methoataske, accompanied those Shawnees who migrated to Missouri, later died. Raised by an older sister, Tecumpease, Tecumseh would play war games with other fellow youths in his tribe. Tecumseh accompanied an older brother, Chiksika, on a series of raids against frontier settlements in Kentucky and Tennessee in the late 1780’s. Chiksika had a vision that he would not survive the battle at Buchanan’s station he went ahead as plan and attacked the stockade and was mortally wounded and was carried from the battle field and the dying warrior asked not to be buried but to be placed on a hill. Tecumseh and the other’s retreated back to a Cherokee village where most went back to Ohio while Tecumseh and some other warriors stayed behind. After that Tecumseh went on mostly hunting but occasionally attacking settler’s. After that moved back towards home and come to find out that the Shawnee’s had moved on to where it’s much safer. The battle of Fallen Timber’s broke confidence in British assistance as well as many casualties. Pissed off by the Indian defeat, he refused to sign the Treaty of Greenville (1795). In the 1800’s Tecumseh began to show signs of a prominent war chief. He led a group of yong Indian warriors to a village on the White River in east-central Indiana. There in 1805 Lalawethika ex...

Shangri-La Hotels and Landmarks Berhad (Malaysia)

For the hospitality industry, the average revenue they earn through their continued operations within year 2007 to year 2009 increased in year 2008 and then decline in year 2009. The reason revenue decline in year 2009 is probably is the side effect of the bad economy during end of year 2008. For Landmarks Berhad, their business decline for three years continuously. This shows that their management level is not done their job perfectly. The average revenue for year 2008 should be higher than the previous year; this is happened on the Shangri-La Hotels but not on Landmarks Berhad. They could use the bad situation of our economy as the main reason for the decline in revenue for year 2009 but not for year 2008. Besides that, when we look at the average liquidity of hospitality industry, their average should be around 1. 5 or less since the largest inventories held by a hotel are in the form of guest rooms, and these are included under property, plant and equipment which is a part of fixed assets. Therefore hotels can operate with a liquidity ratio less than 1. 5. Creditors might prefer to see a high ratio of current assets to liabilities since it provides a positive indicator of that particular company’s capability to repay its debt obligations. However for the owner of the company in hospitality industry, a high ratio in liquidity may indicate that more money is being tied up in working capital and is not used nicely. Generally the owner of a hotel company will try to maintain the current ratio which is at the acceptable to ownership and creditors. Furthermore, when we look at the activity ratio, Landmarks berhad’s average collection period and average payment period is much higher than Shangri-La Hotels; and the inventory turnover ratio shows that Landmarks is not being used their total asset effectively. These show that the risk taking by the company operation is higher as well. May be we can’t deny that the earnings of Landmarks Berhad in year 2007 is very higher compare to the average revenue of Shangri-La Hotels, but majority of the earnings of Landmarks Berhad in year 2007 were earned by sold their current asset (total asset held for sale) from discontinued operations. The average revenue of Landmarks Berhad gained from sale was actually much lower than the average compared to the Shangri-La Hotels. This shows that their return is very unstable compared to the Shangri-La Hotels. Thus, we could suggest that Shangri-La Hotels (M) Berhad is the best company compared to Landmarks Berhad.